Specialty Pharma Journal Specialty, Precision & Technology
SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Veracyte, Inc. (Nasdaq: VCYT) announced today that new findings from six studies reinforcing the “real world” performance of the next-generation Afirma Genomic Sequencing Classifier (GSC) and the Afirma Xpression Atlas in thyroid cancer diagnosis were presented at the 88th Annual Meeting of the American Thyroid Association (ATA). The …
Tag Archives: Veracyte
October, 2018
September, 2018
-
27 September
Veracyte to Present New Data Reinforcing Clinical Value of Genomic Tests In Lung Disease Diagnoses
SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Veracyte, Inc. (NASDAQ: VCYT) announced that new data highlighting the ability of the Percepta Bronchial Genomic Classifier to reduce unnecessary invasive procedures in lung cancer diagnosis will be shared in an oral presentation at CHEST 2018, the annual meeting of the American College of Chest Physicians®. In …
November, 2017
-
28 November
Data Confirms Analytical Validity of Veracyte’s Envisia Genomic Classifier for Use in IPF Diagnosis
SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Veracyte, Inc. (NASDAQ: VCYT) announced that data confirming the analytical validity of the company’s Envisia™ Genomic Classifier have been published online in the journal BMC Pulmonary Medicine. The findings add to the growing body of evidence, including previously reported clinical validity and clinical utility data, supporting the use …
October, 2017
-
20 October
Veracyte Presents New Data Validating Accuracy of BRAF V600E and Parathyroid Tissue Classifiers
SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Veracyte, Inc. (NASDAQ: VCYT) announced that data presented at the 87th Annual Meeting of the American Thyroid Association (ATA) being held October 18-22 in Victoria, BC, Canada demonstrate the accuracy of identification of BRAF V600E and parathyroid tissue through new classifiers developed in conjunction with the next-generation Afirma …
May, 2017
-
5 May
Veracyte Announces Next-Generation Afirma Test Can Help More Patients Avoid Unnecessary Surgery in Thyroid Cancer Diagnosis
SOUTH SAN FRANCISCO, Calif., May 4, 2017 /PRNewswire/ — Veracyte, Inc. (NASDAQ: VCYT), a genomic diagnostics company focused on reducing unnecessary surgeries and healthcare costs by resolving diagnostic uncertainty, today announced data from a pivotal clinical validation study of its Afirma Genomic Sequencing Classifier (GSC). The data suggest that the …
April, 2015
-
14 April
Veracyte and GE Partner to Develop New Diagnostic Approaches
Molecular diagnostic company Veracyte, Inc. announced it is teaming up with GE to develop new diagnostic approaches to address unmet clinical needs. Veracyte and GE announced a research collaboration to develop new solutions that can improve disease diagnosis. Veracyte will collaborate with GE Ventures, GE Healthcare and the GE Global …